Malignancy‐associated immune responses: Lessons from human inborn errors of immunity
Open Access
- 19 June 2023
- journal article
- review article
- Published by Wiley in Immunology
- Vol. 170 (3) , 319-333
Abstract
It is widely understood that cancer is a significant cause of morbidity and mortality worldwide. Despite numerous available treatments, prognosis for many remains poor, thus, the development of novel therapies remains essential. Given the incredible success of many immunotherapies in this field, the important contribution of the immune system to the control, and elimination, of malignancy is clear. While many immunotherapies target higher-order pathways, for example, through promoting T-cell activation via immune checkpoint blockade, the potential to target specific immunological pathways is largely not well researched. Precisely understanding how immunity can be tailored to respond to specific challenges is an exciting idea with great potential, and may trigger the development of new therapies for cancer. Inborn Errors of Immunity (IEI) are a group of rare congenital disorders caused by gene mutations that result in immune dysregulation. This heterogeneous group, spanning widespread, multisystem immunopathology to specific immune cell defects, primarily manifest in immunodeficiency symptoms. Thus, these patients are particularly susceptible to life-threatening infection, autoimmunity and malignancy, making IEI an especially complex group of diseases. While precise mechanisms of IEI-induced malignancy have not yet been fully elucidated, analysis of these conditions can highlight the importance of particular genes, and downstream immune responses, in carcinogenesis and may help inform mechanisms which can be utilised in novel immunotherapies. In this review, we examine the links between IEIs and cancer, establishing potential connections between immune dysfunction and malignancy and suggesting roles for specific immunological mechanisms involved in preventing carcinogenesis, thus, guiding essential future research focused on cancer immunotherapy and providing valuable insight into the workings of the immune system in both health and disease.Keywords
This publication has 100 references indexed in Scilit:
- T-Regulatory Cells: Key Players in Tumor Immune Escape and AngiogenesisCancer Research, 2012
- Second messenger role for Mg2+ revealed by human T-cell immunodeficiencyNature, 2011
- Selective IgA DeficiencyJournal of Clinical Immunology, 2010
- Combined Immunodeficiency Associated withDOCK8MutationsNew England Journal of Medicine, 2009
- Insertional Transformation of Hematopoietic Cells by Self-inactivating Lentiviral and Gammaretroviral VectorsMolecular Therapy, 2009
- Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinomaBritish Journal of Cancer, 2009
- Immunodeficiency in ataxia telangiectasia is correlated strongly with the presence of two null mutations in the ataxia telangiectasia mutated geneClinical and Experimental Immunology, 2008
- Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapyProceedings of the National Academy of Sciences, 2006
- A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined ImmunodeficiencyNew England Journal of Medicine, 2003
- The Immunological Synapse: A Molecular Machine Controlling T Cell ActivationScience, 1999